Executive Summary for HealthEquity Investors

By Naomi Wentworth • Friday, November 18 09:46 • Permanent Link

Shares of Healthcare sector company HealthEquity moved 1.0% today, and are now trading at a price of $61.31. The mid-cap stock's daily volume was 66,404 compared to its average volume of 836,787. The S&P 500 index returned a 0.5% performance.

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company is based in Draper and has 3,688 full time employees. Its market capitalization is $5,182,577,664.

14 analysts are following HealthEquity and have set target prices ranging from $68 to $104 per share. On average, they have given the company a rating of buy. At today's prices, HQY is trading -24.64% away from its average analyst target price of $81.36 per share.

Over the last year, HQY shares have gone down by -1.0%, which represents a difference of 15.0% when compared to the S&P 500. The stock's 52 week high is $79.2 per share and its 52 week low is $36.8. With average free cash flows of $126,972,500.0 that have been growing at an average rate of 13.3% over the last four years, HealthEquity declining stock performance may not be reflective of the quality of its underlying business.

For a deeper fundamental analysis into HealthEquity and other market moving stocks, subscribe to our free newsletter today!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.